Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation

NCT03535415 is registered in ClinicalTrials.gov with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03535415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03535415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation
Lead sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
June 25, 2018
Completion date
September 30, 2021
Enrollment
68 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

dwarfism